Patents Examined by S. J. Friedman
  • Patent number: 5240954
    Abstract: The invention relates to the use of compounds of the general formula (I) ##STR1## wherein R.sup.1 represents a hydrogen atom or a C.sub.1-10 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkyl-(C.sub.1-4) alkyl, C.sub.3-6 alkenyl, C.sub.3-10 alkynyl, phenyl or phenyl-C.sub.1-3 alkyl group; and one of the groups represented byR.sup.2, R.sup.3 and R.sup.4 is a hydrogen atom or a C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.2-6 alkenyl or phenyl-C.sub.1-3 alkyl group and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C.sub.1-6 alkyl group; and physiologically acceptable salts and solvates thereof, for the relief of nausea and vomiting and/or the promotion of gastric emptying and for the manufacture of a medicament for this purpose. Promotion of gastric emptying may be for the relief of gastro-intestinal disorders associated with gastric stasis or may be of advantage in radiological examination procedures.
    Type: Grant
    Filed: December 9, 1991
    Date of Patent: August 31, 1993
    Assignee: Glaxo Group Limited
    Inventors: Michael B. Tyers, Ian H. Coates, David C. Humber, George B. Ewan, James A. Bell
  • Patent number: 5236908
    Abstract: The invention provides methods for preventing neural tissue damage caused by injury to the central nervous system (CNS) by the administration of a therapeutically effective amount of an adenosinergic agent. One aspect of the invention is directed toward continuous administration of a therapeutically effective amount of an adenosinergic agent for a period of time sufficient to prevent neural tissue damage. In another aspect of the present invention, the adenosinergic agents may be administered on several occasions during the prolonged period of treatment, so long as the doses of adenosinergic agents are spaced in time so that a therapeutically effective concentration of adenosinergic agent is maintained for a period of time sufficient to prevent neural tissue damage.
    Type: Grant
    Filed: June 7, 1991
    Date of Patent: August 17, 1993
    Assignee: Gensia Pharmaceuticals, Inc.
    Inventors: Harry E. Gruber, Leonard P. Miller
  • Patent number: 5236700
    Abstract: Oral compositions containing a gastroprotective amount of zirconium aluminum glycinate, aluminum chlorohydrate or a mixture thereof are disclosed. A method for protecting the gastric mucosa against injury caused by a gastric irritant such as NSAIDs is also disclosed.
    Type: Grant
    Filed: September 23, 1992
    Date of Patent: August 17, 1993
    Assignee: Bristol-Myers Squibb Company
    Inventors: Randy Koslo, Alison Lukacsko
  • Patent number: 5234909
    Abstract: Dipeptidic amides having the formula, RCO--NHCH.sub.2 CONH--CH(CH.sub.2 0H)--COOH wherein R is a linear or branched alkyl group, optionally unsaturated and containing 7 to 17 carbon atoms, are used in cosmetic or pharmaceutical compositions for the treatment or care of the skin.
    Type: Grant
    Filed: February 6, 1992
    Date of Patent: August 10, 1993
    Assignee: L'Oreal
    Inventor: Michel Philippe
  • Patent number: 5234956
    Abstract: Disclosed is a method for reducing NMDA receptor-mediated neuronal damage in a mammal by administering to the mammal a nitric-oxide generating compound, or a physiologically acceptable salt thereof, in a concentration effective to cause such reduction. Also disclosed is a method for reducing NMDA receptor-mediated neuronal damage in a mammal by administering to the mammal nitroprusside, nitroglycerin, or a derivative of one of those compounds, in a concentration effective to cause such reduction.
    Type: Grant
    Filed: September 22, 1992
    Date of Patent: August 10, 1993
    Assignee: The Children's Medical Center Corporation
    Inventor: Stuart A. Lipton
  • Patent number: 5234929
    Abstract: A method of treating or preventing motion sickness is disclosed which comprises administering an anti-motion sickness effective amount of an anticonvulsant compound such as phenytoin, ethotoin, primidone, ethosuximide or carbamazepine, in combination with a potentiating amount of an antitussive or cough suppressant agent such as dextromethorphan, levopropoxyphene, muscaphene, pholocodeine, or carbetapentene. The antitussive compounds of the present invention act as potentiating agents so as to enable effective treatment or prevention of motion sickness using a reduced amount of the anticonvulsant compound normally used in such treatment. The method of the present invention reduces the potential for various side effects and thus provides a safer and more effective method of treatment for motion sickness than prior art methods.
    Type: Grant
    Filed: July 20, 1992
    Date of Patent: August 10, 1993
    Inventor: William Chelen
  • Patent number: 5234947
    Abstract: A method for activating potassium channels and for treating hypertension, addiction, asthma, incontinence, and other conditions treatable by potassium channel activators, such as spasms and convulsions, comprising administering a compound having the formula: ##STR1## wherein R is a saturated or unsaturated group having from 1 to 4 carbon atoms which is optionally substituted by lower alkyl, lower alkenyl or lower alkoxy groups; andwherein R' is hydrogen, lower alkyl, lower alkenyl, or aralkyl.
    Type: Grant
    Filed: November 7, 1991
    Date of Patent: August 10, 1993
    Assignee: New York University
    Inventor: Bruce Cherksey
  • Patent number: 5234922
    Abstract: Methods for the treatment of secretory diarrhea comprised of administering to a patient in need thereof, an effective amount of a CFTR chloride channel blocker or a potassium channel opener are disclosed. The CFTR chloride channel blocker is a sulfonylurea of the group consisting of tolbutamide, glibenclamide, and related analogs. The potassium channel opener is selected from the group consisting of diazoxide, lemakalim, and minoxidil sulfate.
    Type: Grant
    Filed: September 28, 1992
    Date of Patent: August 10, 1993
    Assignee: University of Iowa Research Foundation
    Inventors: Michael J. Welsh, David N. Sheppard
  • Patent number: 5234927
    Abstract: A stable solid pharmaceutical composition for oral administration comprising dapiprazole or a physiologically acceptable acid salt thereof together with a pharmaceutically acceptable inert excipient and magnesium oxide as a degradation retarding agent is disclosed.
    Type: Grant
    Filed: July 20, 1992
    Date of Patent: August 10, 1993
    Assignee: Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
    Inventors: Depalmo Galli Angeli, Leandro Baiocchi
  • Patent number: 5232933
    Abstract: Patients suffering from neurodegenerative diseases are treated by administering an effective amount of an alpha-nicotine type compound.
    Type: Grant
    Filed: May 21, 1992
    Date of Patent: August 3, 1993
    Assignee: R. J. Reynolds Tobacco Company
    Inventors: Patrick M. Lippiello, William S. Caldwell
  • Patent number: 5232934
    Abstract: A method of treatment is provided for reducing or eliminating psychomotor addiction in mammalian subjects, employing as an active agent 3-phenoxypyridine or a pharmaceutically acceptable acid-addition salt thereof.
    Type: Grant
    Filed: July 17, 1992
    Date of Patent: August 3, 1993
    Assignee: Warner-Lambert Co.
    Inventor: David Downs
  • Patent number: 5232932
    Abstract: Patients suffering from neurodegenerative diseases are treated by administering an effective amount of a pseudooxynicotine compound.
    Type: Grant
    Filed: May 21, 1992
    Date of Patent: August 3, 1993
    Assignee: R. J. Reynolds Tobacco Company
    Inventors: William S. Caldwell, Patrick M. Lippiello
  • Patent number: 5231099
    Abstract: The invention relates to a method of treating psychosis in a mammal which comprises administering to the mammal an effective amount of a dopamine receptor antagonist antipsychotic and a sigma receptor antagonist having greater affinity for sigma receptors than for dopamine receptors, in an amount effective to selectively enhance the antipsychotic effects of the dopamine receptor antagonist relative to the adverse side effects of the dopamine receptor antagonist.
    Type: Grant
    Filed: April 15, 1991
    Date of Patent: July 27, 1993
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventor: Leonard Cook
  • Patent number: 5231108
    Abstract: Analogs of 6-mercaptopurine have been found to enhance the detoxification of various electrophilic toxicants in vivo, while having minimal cytotoxicity themselves. This property allows such compounds to act as scavengers for electrophilic toxicants, thereby preventing the cellular damage caused by such toxic agents.
    Type: Grant
    Filed: March 4, 1992
    Date of Patent: July 27, 1993
    Assignee: The Board of Regents, The University of Texas System
    Inventor: Michael C. MacLeod
  • Patent number: 5231080
    Abstract: The invention relates to a method for the treatment of atherosclerosis, thrombosis and/or of peripheral vessel disease by administration of angiotensin converting enzyme inhibitors. Administration of compounds of the formula I ##STR1## in which n is 1 or 2, R, R.sup.1, R.sup.2 and R.sup.3 are identical or different and each denotes hydrogen or an organic radical, and R.sup.4 and R.sup.5 form, together with the atoms carrying them, a mono-, bi- or tricyclic heterocyclic ring system, is preferred. The invention also relates to angiotensin converting enzyme inhibitors and to agents containing them for administration for the treatment of the abovementioned diseases.
    Type: Grant
    Filed: March 29, 1991
    Date of Patent: July 27, 1993
    Assignee: Hoechst Aktiengesellschaft
    Inventor: Bernward Scholkens
  • Patent number: 5229389
    Abstract: The invention concerns the use of i.a. 1-[2-(2-naphthyl)-ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyr idine and its pharmaceutically acceptable addition salts for the preparation of medicaments suitable for the treatment and/or prophylaxis of neuronal degenerative processes including senile dementia, vascular dementia, and Alzheimer's disease.
    Type: Grant
    Filed: May 21, 1991
    Date of Patent: July 20, 1993
    Assignee: SANOFI
    Inventors: Francois X. Coude, Jacqueline Fournier, Umberto Guzzi
  • Patent number: 5229405
    Abstract: Compounds of the formula I ##STR1## in which R.sub.1 is lower alk-2-en-1-yl, lower alk-3-en-2-yl, lower alk-2-yn-1-yl or lower alkyl substituted in the 2,3-position by radicals which can be eliminated to give a double bond, R.sub.2 is hydrogen and R.sub.3 is methyl which is unsubstituted or substituted by radicals which can be eliminated together with hydrogen R.sub.2 to give a double bond or R.sub.2 and R.sub.3 are both hydrogen or lower alkyl or are together methylene and R.sub.4 is a group of the formula Ia, Ib or Ic ##STR2## in which R.sub.5 is hydrogen, lower alkyl, lower alk-2-en-1-yl or lower alk-2-yn-1-yl and R.sub.6 is a group of the formula Id or Ie ##STR3## in which R.sub.1, R.sub.2, R.sub.3 and R.sub.5 are as defined, and their pharmaceutically acceptable salts can be used in a novel manner for the treatment of diseases of the rheumatoid type.
    Type: Grant
    Filed: April 10, 1992
    Date of Patent: July 20, 1993
    Assignee: Ciba-Geigy Corporation
    Inventors: Ulrich Feige, Irmgard Wiesenberg, Leo Widler, Pier G. Ferrini, Martin Missbach
  • Patent number: 5229407
    Abstract: The invention relates to the use of compounds of formula (I) ##STR1## wherein Im represents an imidazolyl group of formula: ##STR2## and R.sup.1 represents a hydrogen atom or a group selected from C.sub.1-6 alkyl, C.sub.3-6 alkenyl, C.sub.3-10 alkynyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylC.sub.1-4 alkyl, phenyl, phenylC.sub.1-3 alkyl, phenylmethoxymethyl, phenoxyethyl, phenoxymethyl, --CO.sub.2 R.sup.5, --COR.sup.5, --CONR.sup.5 R.sup.6 or --SO.sub.2 R.sup.5 (wherein R.sup.5 and R.sup.6, which may be the same or different, each represents a hydrogen atom, a C.sub.1-6 alkyl or C.sub.3-7 cycloalkyl group, or a phenyl or phenylC.sub.1-4 alkyl group, in which the phenyl group is optionally substituted by one or more C.sub.1-4 alkyl, C.sub.1-4 alkoxy or hydroxy groups or halogen atoms, with the proviso that R.sup.5 does not represent a hydrogen atom when R.sup.1 represents a group --CO.sub.2 R.sup.5 or --SO.sub.2 R.sup.5);one of the groups represented by R.sup.2, R.sup.3 and R.sup.
    Type: Grant
    Filed: July 10, 1992
    Date of Patent: July 20, 1993
    Assignee: Glaxo Group Limited
    Inventors: Ian H. Coates, Alexander W. Oxford, Peter C. North, Michael B. Tyers
  • Patent number: 5227385
    Abstract: Patients suffering from neurodegenerative diseases are treated by administering an effective amount of a ferruginine compound or a anhydroecgonine compound.
    Type: Grant
    Filed: March 13, 1992
    Date of Patent: July 13, 1993
    Assignees: Wake Forest University, R. J. Reynolds Tobacco Company
    Inventors: William S. Caldwell, Huw M. L. Davies, Patrick M. Lippiello
  • Patent number: 5227391
    Abstract: Patients suffering from neurodegenerative diseases are treated by administering an effective amount of an (R)-(+)-nicotine compound.
    Type: Grant
    Filed: April 10, 1992
    Date of Patent: July 13, 1993
    Assignee: R. J. Reynolds Tobacco Company
    Inventors: William S. Caldwell, Patrick M. Lippiello